<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02682836</url>
  </required_header>
  <id_info>
    <org_study_id>LCCC1537</org_study_id>
    <nct_id>NCT02682836</nct_id>
  </id_info>
  <brief_title>Physical Activity to Maintain Quality of Life and Physical Function in Women With Metastatic Breast Cancer: a Pilot Study</brief_title>
  <official_title>Physical Activity to Maintain Quality of Life and Physical Function in Women With Metastatic Breast Cancer: a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNC Lineberger Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UNC Lineberger Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Metastatic breast cancer (MBC) is an incurable disease. Maintaining optimum quality of life&#xD;
      is a major goal of care. There is a strong body of evidence that exercise can reduce or&#xD;
      manage fatigue, depression and insomnia in breast cancer patients; however, the evidence base&#xD;
      is overwhelmingly in early stage cancer patients. The purpose of this study is to see if a&#xD;
      home-based, self-directed walking program can have similar benefits in women with an MBC&#xD;
      diagnosis. The primary objective is to evaluate whether engagement in physical activity will&#xD;
      reduce fatigue during active treatment for MBC (baseline to 3 months); this is the primary&#xD;
      endpoint. Secondary objectives pertain to feasibility of recruitment and retention of study&#xD;
      participants and measuring changes between baseline, 3 months and 6 months in additional&#xD;
      quality of life measures. Exploratory analyses pertain to changes in p16INK4a levels and&#xD;
      sarcopenia between baseline and 3 months. The design is a single arm intervention trial in 30&#xD;
      patients. Findings from this study will provide preliminary data for a grant application to&#xD;
      test the physical activity intervention in a randomized controlled trial (RCT) in a large&#xD;
      sample of women with metastatic breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 2015</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Actual">October 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>changes in fatigue scores</measure>
    <time_frame>at 3 months</time_frame>
    <description>Evaluate change in PROMIS Fatigue scores from baseline to 3 months</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>single arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Walk with Ease physical activity intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Walk with Ease</intervention_name>
    <arm_group_label>single arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female&#xD;
&#xD;
          -  Age 21 or older&#xD;
&#xD;
          -  Metastatic breast cancer (MBC) diagnosis - Stage IV&#xD;
&#xD;
          -  Receiving treatment regimen for MBC, but no more than 3 previous chemotherapy or&#xD;
             biologic regimens&#xD;
&#xD;
          -  Approval from the treating clinician to engage in moderate-intensity physical&#xD;
             activity.&#xD;
&#xD;
          -  Patient-assessed ability to walk and engage in moderate physical activity&#xD;
&#xD;
          -  Proficient in English.&#xD;
&#xD;
          -  IRB approved signed written informed consent.&#xD;
&#xD;
          -  Willing and able to do all study requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  One or more significant medical conditions or other issues that in the physician's&#xD;
             judgment preclude participation in the walking intervention.&#xD;
&#xD;
          -  No more than 3 prior chemotherapy regimens.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kirsten A Nyrop, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UNC Lineberger Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UNC Cancer Hospital</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 10, 2016</study_first_submitted>
  <study_first_submitted_qc>February 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2016</study_first_posted>
  <last_update_submitted>May 28, 2021</last_update_submitted>
  <last_update_submitted_qc>May 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>physical activity</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>fatigue</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

